PSNL - Personalis Quarterly EPS earnings growth

Personalis Genomics - graphic logo of issuer PSNL

Personalis, Inc. aims to scale genomic analysis through alliances with pharmaceutical behemoths. The quarterly EPS growth demonstrates progress on this path, where -28.60 characterizes this valuation parameter. However, the precision of the NeXt platform and confidence in management create high barriers to entry for competitors, protecting the uniqueness of these cancer treatment methods.

personalis.com (PSNL) Year-over-year net earnings per share trend for the last twelve months: for the period 07/04/2022 - 11/15/2026

personalis.com (PSNL) - metric breakdowns and financial figures

- market value and analyst target forecast:
Price Chart Personalis Corp|PSNL - Fair Value Consensus
- market capitalization statistics:
Market Capitalization Personalis Corp|PSNL - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Personalis|PSNL - Net Asset Value|Market Capitalization to Book Value Ratio personalis.com|PSNL - Company Assets
- company liabilities and liquidity data:
Debt to Equity Personalis, Inc.|PSNL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Personalis Inc|PSNL - Company Total Debt Obligations|Debt to Book Capitalization Ratio Personalis Corp|PSNL - Long-Term Debt|Company Short-Term Debt Personalis|Quick Ratio personalis.com
- earnings and market multiples details:
PSNL - Net Profit|Expected Profit Personalis, Inc.|PSNL - Price to Earnings Ratio|Forward P/E Multiple personalis.com|PSNL - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Personalis Inc|PSNL - Operating income before deduction of amortization|Net earnings per share for the last 12 months Personalis|PSNL - Earnings per share for the trailing year|Quarterly EPS earnings growth personalis.com|PSNL - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Personalis, Inc.
- issuer revenue and sales details:
PSNL - Company Sales Volume|Projected Sales Volume Personalis Genomics|PSNL - Market Cap to Revenue|Forward Price-to-Revenue Multiple Personalis Inc|PSNL - Annual Revenue Growth (Last Twelve Months)
Analysis of all company metrics:Personalis, Inc.
Manufactured product of Personalis, Inc.

This indicator calculates earnings per share (EPS) dynamics by measuring net income growth rates between quarters. The formula is sensitive to operational shifts, identifying hidden business degradation prior to official reports. By analyzing the quarterly EPS trajectory, an investor gains insight into the real balance of supply and demand. For Personalis, Inc. (PSNL), such fluctuations reflect the risks of biosample logistics disruptions caused by geopolitical confrontation, which directly impacts the efficiency of DNA therapy development.

Analysis of competing companies

ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Year-over-year earnings per one share growth for the last 12 months ERAS|DCTH - Year-over-year earnings per share growth for the last twelve months|Y-mAbs Therapeutics (YMAB) - Year-over-year net earnings per share growth for the last 12 months|AURA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months CADL|Year-over-year earnings per share growth for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|Year-over-year net earnings per share change for the last twelve months Citius Oncology|TuHURA Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Protara TARA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)